Baricitinib for Graft-Versus-Host Disease Prophylaxis after HLA-matched Hematopoietic Cell Transplantation

Abstract Acute graft-versus-host disease (aGVHD) is a leading cause of non-relapse mortality after allogeneic peripheral blood hematopoietic cell transplant (PB-HCT). The role of baricitinib, a balanced JAK1/2 inhibitor, for GvHD prophylaxis is unknown. Baricitinib after HLA-matched allogeneic PB-HCT was studied in a single-arm, open-label, phase I trial in 24 subjects. Subjects received baricitinib at 2 or 4 mg daily from days − 3 to + 100 post PB-HCT, followed by a taper. No primary graft failure, delayed engraftment or grade III/IV adverse events were observed. Overall incidence of grade III/IV aGVHD was 12.5% (3/24), of which 2/3 occurred after baricitinib discontinuation. Mild-moderate chronic GVHD occurred in 45.8% subjects, with no cases of severe chronic GVHD. Transplant-related mortality at day + 180 was 8% (2/24). The 1-year OS was 70% (95% CI 48–85%), PFS 62% (95% CI 40–78%), and refined GVHD and relapse free survival (GRFS) 33% (95% CI 15–52%). Correlative studies confirmed on-target effect of baricitinib resulting in downregulation of JAK1/2 pathways. Baricitinib is safe and tolerable after HLA-matched allogeneic PB-HCT with no episodes of primary graft failure and low rates of grade III/IV acute GVHD while on therapy.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-13
DOI
https://doi.org/10.21203/rs.3.rs-11066216/v1
Primary Topic
Hematopoietic Stem Cell Transplantation
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Baricitinib for Graft-Versus-Host Disease Prophylaxis after HLA-matched Hematopoietic Cell Transplantation

Zachary David Crees, Amanda F. Cashen, Ramzi Abboud, Jeffery King et al.
2 links
Research Square
Hematopoietic Stem Cell Transplantation
preprint

Baricitinib for Graft-Versus-Host Disease Prophylaxis after HLA-matched Hematopoietic Cell Transplantation

Zachary David Crees, Amanda F. Cashen, Ramzi Abboud, Jeffery King, Iskra Pusic, Jaebok Choi, Melinda Harding, Jeremy Eisele, John F. DiPersio, Sena Kim, Arun Čumpelik, Armin Ghobadi, Mark A. Schroeder, Geoffrey L. Uy, Feng Gao, Camille N. Abboud, Peter Westervelt, Meagan A. Jacoby, Sora Lim
preprint en

Abstract

Abstract Acute graft-versus-host disease (aGVHD) is a leading cause of non-relapse mortality after allogeneic peripheral blood hematopoietic cell transplant (PB-HCT). The role of baricitinib, a balanced JAK1/2 inhibitor, for GvHD prophylaxis is unknown. Baricitinib after HLA-matched allogeneic PB-HCT was studied in a single-arm, open-label, phase I trial in 24 subjects. Subjects received baricitinib at 2 or 4 mg daily from days − 3 to + 100 post PB-HCT, followed by a taper. No primary graft failure, delayed engraftment or grade III/IV adverse events were observed. Overall incidence of grade III/IV aGVHD was 12.5% (3/24), of which 2/3 occurred after baricitinib discontinuation. Mild-moderate chronic GVHD occurred in 45.8% subjects, with no cases of severe chronic GVHD. Transplant-related mortality at day + 180 was 8% (2/24). The 1-year OS was 70% (95% CI 48–85%), PFS 62% (95% CI 40–78%), and refined GVHD and relapse free survival (GRFS) 33% (95% CI 15–52%). Correlative studies confirmed on-target effect of baricitinib resulting in downregulation of JAK1/2 pathways. Baricitinib is safe and tolerable after HLA-matched allogeneic PB-HCT with no episodes of primary graft failure and low rates of grade III/IV acute GVHD while on therapy.

Research Square
Washington University in St. Louis (US), MaineHealth (US)
Foundation for Barnes-Jewish Hospital, Institute of Clinical and Translational Sciences, Gabrielle's Angel Foundation for Cancer Research, Alvin J. Siteman Cancer Center, Swim Across America, Incyte, Syndax Pharmaceuticals, Novo Nordisk, National Institutes of Health, National Cancer Institute, National Center for Advancing Translational Sciences
Good health and well-being
Hematopoietic Stem Cell Transplantation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon